Clinical and Molecular Hepatology

Current issue

Volume 30(2) Apr 2024
Print ISSN: 2287-2728
Online ISSN: 2287-285X

Review Comprehensive approach to controlling chronic hepatitis B in China: Shan Shan, Xinyan Zhao, Jidong Jia; Clin Mol Hepatol. 2024;30(2):135-143.

Editorials Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer: Pin-Nan Cheng, Ming-Lung Yu; Clin Mol Hepatol. 2024;30(2):144-146.

Toward hepatitis C virus elimination using artificial intelligence: Moon Haeng Hur, Jeong-Hoon Lee; Clin Mol Hepatol. 2024;30(2):147-149.

Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization: Mohammad Saeid Rezaee-Zavareh, Naomy Kim, Ju Dong Yang; Clin Mol Hepatol. 2024;30(2):150-153.

Enhancing off-nucleos(t)ide analogue outcome predictions in chronic hepatitis B with time-varying hepatitis B core-related antigen: Chen-Te Huang, Tai-Chung Tseng; Clin Mol Hepatol. 2024;30(2):154-156.

Evaluation of the histological scoring systems of autoimmune hepatitis: A significant step towards the optimization of clinical diagnosis: Atsumasa Komori; Clin Mol Hepatol. 2024;30(2):157-159.

Exploring the prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma: Ji Eun Han, Hyo Jung Cho; Clin Mol Hepatol. 2024;30(2):160-163.

Linvencovir: Paving the way for functional cure in hepatitis B: Jiwon Yang, Jonggi Choi; Clin Mol Hepatol. 2024;30(2):164-165.

JCAD, a new potential therapeutic target in cholestatic liver disease: Byoung Kuk Jang; Clin Mol Hepatol. 2024;30(2):166-167.

Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences: Joo Hyun Oh, Dae Won Jun; Clin Mol Hepatol. 2024;30(2):168-170.

Steatotic liver disease: Know your enemies: Lung-Yi Mak; Clin Mol Hepatol. 2024;30(2):171-173.

The gene expression signature of metabolic dysfunction- associated steatotic liver disease from a multiomics perspective: Carlos Jose Pirola, Silvia Sookoian; Clin Mol Hepatol. 2024;30(2):174-176.

Original Articles Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment: Miguel Sogbe, Idoia Bilbao, Francesco P. Marchese, Jon Zazpe, Annarosaria De Vito, Marta Pozuelo, Delia D’Avola, Mercedes Iñarrairaegui, Carmen Berasain, Maria Arechederra, Josepmaria Argemi, Bruno Sangro; Clin Mol Hepatol. 2024;30(2):177-190.

Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients: Jinlin Hou, Edward Gane, Rozalina Balabanska, Wenhong Zhang, Jiming Zhang, Tien Huey Lim, Qing Xie, Chau-Ting Yeh, Sheng-Shun Yang, Xieer Liang, Piyawat Komolmit, Apinya Leerapun, Zenghui Xue, Ethan Chen, Yuchen Zhang, Qiaoqiao Xie, Ting-Tsung Chang, Tsung-Hui Hu, Seng Gee Lim, Wan-Long Chuang, Barbara Leggett, Qingyan Bo, Xue Zhou, Miriam Triyatni, Wen Zhang, Man-Fung Yuen; Clin Mol Hepatol. 2024;30(2):191-205.

JCAD deficiency attenuates activation of hepatic stellate cells and cholestatic fibrosis: Li Xie, Hui Chen, Li Zhang, Yue Ma, Yuan Zhou, Yong-Yu Yang, Chang Liu, Yu-Li Wang, Ya-Jun Yan, Jia Ding, Xiao Teng, Qiang Yang, Xiu-Ping Liu, Jian Wu; Clin Mol Hepatol. 2024;30(2):206-224.

Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study: Michihiro Iwaki, Hideki Fujii, Hideki Hayashi, Hidenori Toyoda, Satoshi Oeda, Hideyuki Hyogo, Miwa Kawanaka, Asahiro Morishita, Kensuke Munekage, Kazuhito Kawata, Tsubasa Tsutsumi, Koji Sawada, Tatsuji Maeshiro, Hiroshi Tobita, Yuichi Yoshida, Masafumi Naito, Asuka Araki, Shingo Arakaki, Takumi Kawaguchi, Hidenao Noritake, Masafumi Ono, Tsutomu Masaki, Satoshi Yasuda, Eiichi Tomita, Masato Yoneda, Akihiro Tokushige, Yoshihiro Kamada, Hirokazu Takahashi, Shinichiro Ueda, Shinichi Aishima, Yoshio Sumida, Atsushi Nakajima, Takeshi Okanoue; Clin Mol Hepatol. 2024;30(2):225-234.

Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis: Michael H. Le, David M. Le, Thomas C. Baez, Hansen Dang, Vy H. Nguyen, KeeSeok Lee, Christopher D. Stave, Takanori Ito, Yuankai Wu, Yee Hui Yeo, Fanpu Ji, Ramsey Cheung, Mindie H. Nguyen; Clin Mol Hepatol. 2024;30(2):235-246.

Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression: Sumin Oh, Yang-Hyun Baek, Sungju Jung, Sumin Yoon, Byeonggeun Kang, Su-hyang Han, Gaeul Park, Je Yeong Ko, Sang-Young Han, Jin-Sook Jeong, Jin-Han Cho, Young-Hoon Roh, Sung-Wook Lee, Gi-Bok Choi, Yong Sun Lee, Won Kim, Rho Hyun Seong, Jong Hoon Park, Yeon-Su Lee, Kyung Hyun Yoo; Clin Mol Hepatol. 2024;30(2):247-262.

Letters to the Editor Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD: Hiroyuki Suzuki, Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Takumi Kawaguchi; Clin Mol Hepatol. 2024;30(2):263-265.

Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease: Tsubasa Tsutsumi, Dan Nakano, Machiko Kawaguchi, Hirokazu Takahashi, Takumi Kawaguchi; Clin Mol Hepatol. 2024;30(2):266-268.

Letter regarding “Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation”: Yun-Fan Liaw; Clin Mol Hepatol. 2024;30(2):269-271.

Correspondences Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer – author’s reply: Hyeyeon Hong, Jonggi Choi; Clin Mol Hepatol. 2024;30(2):272-273.

Correspondence on Letter regarding “Toward hepatitis C virus elimination using artificial intelligence”: Ming-Ying Lu, Ming-Lung Yu; Clin Mol Hepatol. 2024;30(2):274-275.

Optimizing off-treatment outcome predictions: The potential of time-varying HBcrAg and the need for more research: Ying-Nan Tsai, Jia-Ling Wu, Yao-Chun Hsu; Clin Mol Hepatol. 2024;30(2):276-278.

Both liver parenchymal and non-parenchymal cells express JCAD protein under various circumstances: Li Xie, Li Zhang, Hui Chen, Yong-Yu Yang, Jian Wu; Clin Mol Hepatol. 2024;30(2):279-280.

Correspondence on Letter regarding “Prognosis of biopsy-confirmed MASLD: A sub-analysis of the CLIONE study”: Hideki Fujii, Michihiro Iwaki, Yoshihiro Kamada; Clin Mol Hepatol. 2024;30(2):281-283.

In response to: Steatotic liver disease-know your enemies: Michael H. Le, Linda Henry, Mindie H. Nguyen; Clin Mol Hepatol. 2024;30(2):284-286.

Correspondence on Editorial regarding “Identification of signature gene set as highly accurate determination of MASLD progression”: Sungju Jung, Sumin Yoon, Jong Hoon Park, Yeon-Su Lee, Kyung Hyun Yoo; Clin Mol Hepatol. 2024;30(2):287-290.

Reply to: “Evaluation of the histological scoring systems of autoimmune hepatitis: A significant step towards the optimization of clinical diagnosis”: Haeryoung Kim, Sook-Hyang Jeong; Clin Mol Hepatol. 2024;30(2):291-292.

Harnessing hepatitis B core-related antigen measurement to optimize posttreatment monitoring: Ying-Nan Tsai, Jia-Ling Wu, Yao-Chun Hsu; Clin Mol Hepatol. 2024;30(2):293-296.

Reply to Correspondence Correspondence on Letter regarding “Both liver parenchymal and non-parenchymal cells express JCAD proteins under various circumstances”: Byoung Kuk Jang; Clin Mol Hepatol. 2024;30(2):297-298.

Snapshot Immunopathogenesis of liver fibrosis in steatotic liver disease: Chaerin Woo, Won-Il Jeong; Clin Mol Hepatol. 2024;30(2):299-302.